Clinical Trials Browser

Active not recruiting × Everolimus × 90 days × Clear all

NCT03008408 2026-05-22

A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma

Phase 2 Active not recruiting

Endometrial Neoplasms

NCT03114527 2026-05-22

Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)

Phase 2 Active not recruiting

Leiomyosarcoma, Liposarcoma, Sarcoma

NCT02321501 2026-05-20

Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer

Phase 1 Active not recruiting

Neoplasm Metastasis

NCT04195750 2026-05-14

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

Phase 3 Active not recruiting

755 enrolled 28 charts 1 FDA

Carcinoma, Renal Cell, Kidney Neoplasms

NCT01068249 2026-04-30

Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer

Phase 2 Active not recruiting

42 enrolled 11 charts

Recurrence, Endometrial Neoplasms

NCT03616587 2026-04-30

SERENA-1

Phase 1 Active not recruiting

Breast Neoplasms

NCT05306340 2026-04-30

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

Phase 3 Active not recruiting

Breast Neoplasms

NCT03049189 2026-04-06

COMPETE

Phase 3 Active not recruiting

324 enrolled 15 charts

Neuroendocrine Tumors

NCT02962414 2026-04-02

Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment

Phase 3 Active not recruiting

Seizures, Tuberous Sclerosis

NCT05252585 2026-04-02

A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML)

Phase 4 Active not recruiting

Tuberous Sclerosis, Angiomyolipoma

NCT00819546 2026-03-25

RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS

Phase 1 Active not recruiting

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03950609 2026-03-19

Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors

Phase 2 Active not recruiting

Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1